LH - Laboratory Corporation of America Holdings

NYSE - NYSE Delayed Price. Currency in USD
164.41
-0.58 (-0.35%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close164.99
Open163.14
Bid140.00 x 800
Ask164.98 x 800
Day's Range162.91 - 166.65
52 Week Range119.38 - 190.36
Volume666,832
Avg. Volume787,693
Market Cap16.194B
Beta (3Y Monthly)1.23
PE Ratio (TTM)18.65
EPS (TTM)8.81
Earnings DateJul 23, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1994-03-29
1y Target Est174.33
Trade prices are not sourced from all markets
  • American City Business Journals3 days ago

    (PHOTOS) Analyst: LabCorp ripe for Walgreens acquisition

    Raymond James analyst John Ransom this week named two potential targets for Walgreens Boots Alliance (Nasdaq: WBA) – LabCorp and drug wholesaler AmerisourceBergen (NYSE: ABC).

  • Business Wire9 days ago

    LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer

    LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the availability of a newly-approved companion diagnostic by the U.S. Food and Drug Administration (FDA), the therascreen® FGFR mutation assay by RGQ RT-PCR, which is now available for ordering from LabCorp and its Integrated Oncology specialty laboratory.

  • Laboratory Corporation of America Holdings’s (NYSE:LH) Investment Returns Are Lagging Its Industry
    Simply Wall St.11 days ago

    Laboratory Corporation of America Holdings’s (NYSE:LH) Investment Returns Are Lagging Its Industry

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we'll look at Laboratory Corporation of America Holdings (NYSE:LH) and reflect on its potential a...

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Laboratory Corporation of America Holdings.

    Laboratory Corporation of America Holdings NYSE:LHView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for LH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.82 billion over the last one-month into ETFs that hold LH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. LH credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Luminex Corp (LMNX) Q1 2019 Earnings Call Transcript
    Motley Fool12 days ago

    Luminex Corp (LMNX) Q1 2019 Earnings Call Transcript

    LMNX earnings call for the period ending March 31, 2019.

  • Business Wire16 days ago

    LabCorp to Webcast Its Annual Meeting of Shareholders

    LabCorp® (LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 9, 2019, at 9:00 a.m. Eastern Daylight Time via the Company website at www.LabCorp.com. LabCorp (LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care.

  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of LH earnings conference call or presentation 30-Apr-19 1:00pm GMT

    Q1 2019 Laboratory Corporation of America Holdings Earnings Call

  • LH or ALGN: Which Is the Better Value Stock Right Now?
    Zacks18 days ago

    LH or ALGN: Which Is the Better Value Stock Right Now?

    LH vs. ALGN: Which Stock Is the Better Value Option?

  • LabCorp (LH) Q1 Earnings Top Mark, Revenues Lag Estimates
    Zacks19 days ago

    LabCorp (LH) Q1 Earnings Top Mark, Revenues Lag Estimates

    Despite increasing acquisitions and favorable mix, the disposition of certain businesses and the implementation of PAMA are adversely affecting LabCorp's (LH) growth.

  • Laboratory Corp of America Holdings (LH) Q1 2019 Earnings Call Transcript
    Motley Fool19 days ago

    Laboratory Corp of America Holdings (LH) Q1 2019 Earnings Call Transcript

    LH earnings call for the period ending March 31, 2019.

  • Associated Press19 days ago

    LabCorp: 1Q Earnings Snapshot

    On a per-share basis, the Burlington, North Carolina-based company said it had profit of $1.86. Earnings, adjusted for one-time gains and costs, were $2.62 per share. The results beat Wall Street expectations. ...

  • Business Wire19 days ago

    LabCorp Announces 2019 First Quarter Results and Increases 2019 Earnings Guidance

    BURLINGTON, N.C.-- -- Q1 revenue of $2.79 billion, down 2% from $2.85 billion last year Q1 diluted EPS of $1.86, up 11% from $1.67 last year; Q1 adjusted EPS of $2.62, down 6% from $2.78 last year 2019 adjusted EPS guidance increased to $11.05 to $11.45, from $11.00 to $11.40 2019 free cash flow guidance of $950 million to $1.05 billion, unchanged from prior guidance LabCorp® today announced results ...

  • Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?
    Zacks24 days ago

    Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?

    Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.

  • LabCorp (LH) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks26 days ago

    LabCorp (LH) Expected to Beat Earnings Estimates: Should You Buy?

    LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire26 days ago

    OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment Agreement

    OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (LH), a leading global life sciences company, announced today an extension of their exclusive distribution agreement as well as an additional investment by LabCorp. The distribution agreement and LabCorp’s initial investment in OmniSeq’s Series B financing round were first announced in August 2017. The distribution agreement originally provided LabCorp with exclusive distribution rights for the OmniSeq Comprehensive and Immune Report Card clinical assays.

  • Moody's26 days ago

    Envigo Laboratories Inc. -- Moody's announces completion of a periodic review of ratings of Envigo Laboratories Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Envigo Laboratories Inc. New York, April 22, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Envigo Laboratories Inc. ("Envigo") and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Moody's27 days ago

    Envigo Laboratories Inc. -- Moody's places Envigo's ratings under review for upgrade following LabCorp deal announcement

    Moody's Investors Service ("Moody's") placed the ratings of Envigo Laboratories Inc. under review for upgrade. Ratings under review for upgrade include the Caa2 Corporate Family Rating, Caa2-PD Probability of Default Rating, the B3 senior secured first lien credit facilities and Caa3 senior secured second lien credit facilities. The announced sale of Envigo's nonclinical contract research services business to LabCorp and the concurrent acquisition of LabCorp's US research models and services business is credit positive given the improvement in liquidity due to net proceeds to be received of $485 million.

  • Moody'slast month

    Laboratory Corporation of America Holdings -- Moody's announces completion of a periodic review of ratings of Laboratory Corporation of America Holdings

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Laboratory Corporation of America Holdings and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
    Zackslast month

    Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?

    Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.

  • What's in Store for Align Technology (ALGN) in Q1 Earnings?
    Zackslast month

    What's in Store for Align Technology (ALGN) in Q1 Earnings?

    Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.

  • Laboratory Corporation of America Holdings (NYSE:LH) Has A ROE Of 13%
    Simply Wall St.last month

    Laboratory Corporation of America Holdings (NYSE:LH) Has A ROE Of 13%

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, we'l...

  • LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider
    Business Wirelast month

    LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider

    BURLINGTON, N.C. & EAST MILLSTONE, N.J.-- -- LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models and services business will purchase Covance’s research products business located in the United States, combining two complementary businesses into a new comprehensive ...

  • Sherwin-Williams Shareholders Elect New Directors
    PR Newswirelast month

    Sherwin-Williams Shareholders Elect New Directors

    Kerrii B. Anderson, former CEO and President of Wendy's International, Inc., and Jeff M. Fettig, former Chairman and CEO of Whirlpool Corporation, join the Board CLEVELAND , April 17, 2019 /PRNewswire/ ...

  • 3 Stocks That Survived Reverse Splits
    Motley Foollast month

    3 Stocks That Survived Reverse Splits

    Rite Aid's board clears the way for a 1-for-20 reverse stock split later this month. Booking Holdings, LabCorp, and Citi have gone on to move higher after going this route.